文献速递肝病

吡格列酮在非酒精性脂肪性肝炎中的浓度依赖性反应

Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-05-03

本研究评估非酒精性脂肪性肝炎(NASH)患者接受吡格列酮45 mg/日治疗18个月后,药物及其活性代谢物浓度与治疗结局的关系。结果显示,吡格列酮浓度及暴露指数与NAFLD活动评分、脂肪变和炎症的改善显著相关,NASH缓解者的暴露指数更高。

要点

  • 吡格列酮浓度与暴露指数均与NAFLD活动评分变化显著相关(r=.48,P=.0002;r=.51,P<.0001)。
  • NASH缓解者的吡格列酮暴露指数高于未缓解者(2.85±1.38 vs 1.78±1.48,P=.018)。
  • 包含基线NAFLD活动评分和暴露指数的预测模型对主要结局的AUC为0.77。

核心结论

  • 本研究证明吡格列酮暴露对NASH患者反应变异的重要性,并提示可能识别最可能从长期吡格列酮治疗中获益患者的潜在因素。

研究设计与样本

  • NASH患者接受吡格列酮45 mg/日治疗18个月,测量吡格列酮浓度,并在基线和治疗后获取肝活检样本。

主要发现

  • 吡格列酮浓度与NAFLD活动评分变化相关(r=.48,P=.0002),暴露指数与NAFLD活动评分变化相关(r=.51,P<.0001)。
  • 吡格列酮浓度与脂肪变变化相关(r=.41,P=.002),暴露指数与脂肪变变化相关(r=.46,P=.0005)。
  • 吡格列酮浓度与炎症变化相关(r=.44,P=.0009),暴露指数与炎症变化相关(r=.40,P=.0003)。
  • 暴露指数与气球样变变化相关(P=.04)。
  • NASH缓解者的暴露指数高于未缓解者(2.85±1.38 vs 1.78±1.48,P=.018)。

关键数值与推荐

  • 主要结局为NAFLD活动评分(NAS)降低≥2分,且超过一个肝组织学分类改善至少1分,同时纤维化无恶化。
  • 吡格列酮暴露指数为考虑吡格列酮及两种活性代谢物浓度的新标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pioglitazone is a safe and effective option to manage patients with type 2 diabetes and nonalcoholic steatohepatitis (NASH). However, there is marked variability in treatment response. AIM: To evaluate the relationship between concentrations of pioglitazone and its active metabolites and treatment outcomes in patients with NASH. METHODS: Pioglitazone concentrations were measured in patients with NASH treated with pioglitazone 45 mg/day for 18 months; liver biopsy samples were obtained at baseline and after treatment. The primary outcome was a ≥2-point reduction in NAFLD activity score (NAS) with at least one-point improvement in more than one liver histology category and without worsening of fibrosis. A novel marker, the pioglitazone exposure index, was calculated to consider the concentrations of pioglitazone as well as the two active metabolites. RESULTS: The response to pioglitazone was concentration-dependent as evidenced by the significant relationship between both pioglitazone concentration and pioglitazone exposure index with changes in NAS (r=.48, P=.0002 and r=.51, P<.0001, respectively), steatosis (r=.41, P=.002 and r=.46, P=.0005), and inflammation (r=.44, P=.0009 and r=.40, P=.0003). The pioglitazone exposure index was also associated with a change in ballooning (P=.04). The pioglitazone exposure index was higher in patients with NASH resolution (2.85±1.38 vs 1.78±1.48, P=.018). A predictive model for the primary outcome was developed that incorporated baseline NAS and pioglitazone exposure index (AUC=0.77). CONCLUSIONS: This study demonstrates the importance of pioglitazone exposure to variable response in patients with NASH, and indicates potential factors that may identify patients most likely to benefit from chronic pioglitazone treatment.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kawaguchi-Suzuki M, Bril F, Kalavalapalli S, et al. Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2017. PMID: 28470881. doi:10.1111/apt.14111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。